| Rank | Status | Study |
|---|
| 1 |
Recruiting
| Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
| Conditions: |
Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction
|
| Interventions: |
Drug: therapeutic testosterone; Other: placebo |
| Outcome Measures: |
The intra-patient change in joint pain at 3 months from baseline as measured by the Brief Pain Inventory for aromatase-inhibitor Arthralgias (BPI-AIA); Safety and tolerability of transdermal testosterone assessed using Common Terminology Criteria for Adverse Events (CTCAE) 4.0 and additional questionnaires, including alopecia, acne, and hirsutism as reported by the patient; The intra-patient change in joint pain and its interference of activity for each month from baseline as measured by BPI-AIA; The change of hot flashes during the first two months from baseline as measured by hot flash diary; The change of libido and menopause-specific quality of life from baseline as measured by MENQOL and POMS monthly
|
|
| 2 |
Recruiting
| Joint Pain and Medication Adherence in Postmenopausal Women Receiving Aromatase Inhibitors
| Conditions: |
Arthralgia; Breast Cancer
|
| Interventions: |
Other: aromatase inhibition therapy - OBSERVATIONAL ONLY; Other: medical chart review; Other: questionnaire administration; Procedure: assessment of therapy complications |
| Outcome Measures: |
Arthralgia incidence, defined as proportion of the baseline population (those who have taken ≥ 9 doses of aromatase inhibitor [AI]) in which new or worsening joint pain or stiffness is observed at 1, 3, and 12 months after beginning AI therapy; Time to onset of Arthralgia (continuous variable in weeks) among baseline population; Arthralgia point prevalence, defined as proportion of the baseline population with a score of ≥ 2 on any one dimension of the outcome measure at 1, 3, and 12 months after beginning AI therapy; Symptom trajectories over the course of treatment; Patient well-being: sleep quality, mood, and physical function
|
|
| 3 |
Recruiting
| Arthralgia of the Temporomandibular Joint. Pain Relief Following One Intra-articular Injection of Methylprednisolone
| Conditions: |
Arthralgia; TMJ
|
| Interventions: |
Drug: Methylprednisolone; Drug: Physiologic saline |
| Outcome Measures: |
VAS pain score change at maximal mouth opening; VAS pain score change at jaw rest; Instrument measures; Adverse events |
|
| 4 |
Recruiting
| Physical Activity to Reduce Joint Pain During Aromatase Inhibitor Therapy
| Conditions: |
Joint Pain; Breast Cancer |
| Intervention: |
Behavioral: Walk with Ease |
| Outcome Measures: |
Self-reported joint pain; Self-reported walking |
|
| 5 |
Not yet recruiting
| Exploratory Study on the Use of Pregabalin for the Treatment of Taxol Related Arthralgia-Myalgia
| Conditions: |
Taxane; Drug-related Side Effects and Adverse Reactions; Pain; Breast Cancer |
| Interventions: |
Drug: Pregabalin; Drug: Placebo |
| Outcome Measures: |
Integrated Numeric Pain Scores and Rescue Analgesic Medication Requirement as calculated by the method proposed by Silverman et al (Silverman, O'Connor et al. 1993).; Numeric Pain Score (NPS); The additional number of hours spent in horizontal position (∆HHP**); FACT-taxane score |
|
| 6 |
Not yet recruiting
| Randomized, Blinded, Sham-controlled Trial of Acupuncture for the Management of Joint Pain in Patients With Psoriasis
| Conditions: |
Psoriasis; Arthralgia
|
| Intervention: |
Other: Acupuncture |
| Outcome Measures: |
Pain measured on the VAS; Improvement in life quality measured with the DLQI (Dermatology Life Quality Index); Approvement in skin lesions |
|
| 7 |
Recruiting
| Yoga for Aromatase Inhibitor-associated Joint Pain
| Condition: |
Breast Cancer |
| Interventions: |
Other: Questionnaires; Other: Yoga Classes |
| Outcome Measures: |
Rate of Study Enrollment; Rate of Study Completion; Occurrence of Reduced Pain Severity; Occurrence of Relief from Other Side Effects |
|
| 8 |
Unknown †
| CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI)
| Conditions: |
Breast Neoplasms; Arthralgia; Arthritis; Genetic Polymorphism
|
| Intervention: |
Drug: Aromatase Inhibitor(Femara or Arimidex) |
| Outcome Measures: |
Change of SNPs (PCR & sequencing), Estrogen, Inflammatory Cytokine level; EORTC (European Organization for Research and Treatment of Cancer)- QOL(Quality of Life)- C30, BR23 & Skeletal pain information, BMI |
|
| 9 |
Recruiting
| RFN for SIJ Disease Study
| Condition: |
Sacro Iliac Joint Pain |
| Intervention: |
Procedure: Comparison of active versus sham radiofrequency neurotomy with Simplicity III |
| Outcome Measures: |
Pain Intensity; Quality of pain; Health related Quality of life; Anxiety and Depression; Functional Disability; Health related quality of life and quality-adjusted life years; Portion of patients randomised to sham requiring rescue therapy with RFN |
|
| 10 |
Recruiting
| S1202: Duloxetine Hydrochloride to Treat Muscle, Bone, and Joint Pain in Pts W/Early-Stage Breast Cancer Receiving Hormone Therapy
| Conditions: |
Breast Cancer; Musculoskeletal Complications; Pain |
| Interventions: |
Drug: duloxetine hydrochloride; Other: placebo |
| Outcome Measures: |
Reduction in average joint pain according to BPI-SF assessed up to 12 weeks; Reduction in worst joint pain according to the BPI-SF worst pain score assessed up to 12 weeks; Reduction in pain interference according to the BPI-SF worst pain score assessed up to 12 weeks |
|
| 11 |
Recruiting
| iFuse Implant System® Minimally Invasive Arthrodesis
| Condition: |
Chronic, Disabling Sacroiliac Joint Pain |
| Interventions: |
Device: iFuse Implant System; Other: Conservative Management |
| Outcome Measures: |
The change in lower back pain as rated by the study subject using a 0-100 visual analog scale (VAS) at 6 months after initiation of treatment; Change from baseline in lower back pain (VAS); Change from baseline in leg pain (VAS; Change in disability due to back pain (ODI; Change in quality of life (EQ-5D; Change in ambulatory and work status; Change in depression score (Zung Depression Scale; Change in objective functional test (ASLR; Change in walking distance; Patient satisfaction and self-rating of disease state; Serious adverse events; Device breakage, loosening and migration |
|
| 12 |
Recruiting
| Antibiotic Treatment of Multiple Erythema Migrans
| Condition: |
Multiple Erythema Migrans |
| Interventions: |
Drug: ceftriaxone; Drug: doxycycline; Other: erythema migrans patients treated with doxycycline |
| Outcome Measures: |
Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, Arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients treated for multiple erythema migrans with ceftriaxone or doxycycline for 15 days.; Comparison of subjective symptoms such as fatigue, malaise, Arthralgias, headache, myalgias, paresthesias, or irritability between patients treated with antibiotic for multiple erythema migrans and control subjects without a history of Lyme borreliosis.; Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, Arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients with solitary versus multiple erythema migrans after antibiotic treatment.
|
|
| 13 |
Recruiting
| Fluoroscopically-guided Versus Landmark-guided Sacroiliac Joint Injections
| Condition: |
Sacroiliac Joint Pain |
| Interventions: |
Drug: Intra-articular sacroiliac joint steroid injection (depomethylprednisolone and bupivacaine); Drug: Landmark guided sacroiliac joint steroid injection (depomethylprednisolone and bupivacaine) |
| Outcome Measures: |
Pain score; Oswestry disability index score; Oswestry disability index |
|
| 14 |
Unknown †
| Synvisc Injections for Lumbar Facet Joint Pain
| Condition: |
Joint Pain |
| Intervention: |
Procedure: Synvisc viscosupplementation |
| Outcome Measures: |
Visual Analogue Scale (VAS) for baseline pain (best, worst, average) and pain while walking; Oswestry Disability Questionnaire; Short Form 36-Item (SF-36); Standing/walking tolerance (defined as time patient can sit for before pain level reaches baseline or distance walked before pain reaches baseline); Analgesic usage; Lumbar range of motion; Patient satisfaction |
|
| 15 |
Recruiting
| High Dose Vitamin D vs Standard Dose Vitamin D Study
| Condition: |
Breast Cancer |
| Interventions: |
Drug: 800 IU Vitamin D Supplement; Drug: 50,000 IU Vitamin D supplement |
| Outcome Measures: |
Efficacy; Compliance with Anti-Cancer Treatment |
|
| 16 |
Recruiting
| Oral Contraceptive During Menopausal Transition
| Condition: |
Perimenopause |
| Interventions: |
Drug: oral contraceptive; Drug: NSAID |
| Outcome Measures: |
improvement in symptoms; quality of life |
|
| 17 |
Recruiting
| Context Effects in Exercise Therapy for Knee and/or Hip Pain
| Conditions: |
Joint Pain; Knee Pain; Hip Pain; Osteoarthritis, Knee; Osteoarthritis, Hip |
| Interventions: |
Other: Contextually enhanced physical surroundings of exercise; Other: Neuromuscular exercise |
| Outcome Measures: |
Patients' Global Perceived Effect; Change from baseline in KOOS (The Knee injury and Osteoarthritis Outcome Score) or HOOS (The Hip Dysfunction and Osteoarthritis Score), respectively; Change from baseline in The 36-item Short-Form Health Survey (SF-36); Change from baseline in Arthritis Self-Efficacy Scale; Patient satisfaction with physical surroundings |
|
| 18 |
Recruiting
| Evaluation Of Efficacy And Safety Of Norspan In Moderate To Severe Pain Due To Osteoarthritis, Rheumatoid Arthritis, Joint/Muscle Pain
| Conditions: |
Osteoarthritis; Rheumatoid Arthritis; Lower Back Pain; Joint Pain; Muscle Pain |
| Intervention: |
Drug: Buprenorphine transdermal patch |
| Outcome Measures: |
Efficacy according to BS-11 pain score; Secondary efficacy outcome; Adverse events |
|
| 19 |
Recruiting
| The Effect of an Exercise Program in Breast Cancer Patients With Joint Pain While Taking Aromatase Inhibitors.
| Condition: |
Women With Estrogen Receptor Positive Breast Cancer Taking Aromatase Inhibitors (AI), Who Are Experiencing Joint Discomfort and Stiffness, |
| Interventions: |
Other: Arm A Directed exercise program; Other: Observation |
| Outcome Measures: |
Pain Disability Index; Plasma levels of inflammatory markers. |
|
| 20 |
Recruiting
| Validity and Reliability of Diagnostic Findings of SI Joint Blocking
| Condition: |
SI Joint Pain |
| Interventions: |
Drug: 0.75% bupivacaine; Drug: .75% bupivacaine |
| Outcome Measures: |
Numeric Rating Scale; Subgroup analysis by diagnosis at 1 month post 3rd block. |
|
